Portfolio Manager Factsheet

February 2016

Biogen had a strong a month, rising 15% due to solid earnings and better than expected guidance for 2017 and the spin-off of the company’s heamophilia business. Coherus Biosciences was lower after the company announced a secondary stock offering at a notable discount to the company’s share price.  

Read more »

Register for email alerts

Worldwide Healthcare Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.